State of New Jersey Common Pension Fund D Purchases 4,554 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

State of New Jersey Common Pension Fund D increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 10.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 49,795 shares of the company’s stock after purchasing an additional 4,554 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Apellis Pharmaceuticals were worth $1,436,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Assenagon Asset Management S.A. increased its holdings in shares of Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after buying an additional 1,409,707 shares during the last quarter. Iron Triangle Partners LP bought a new stake in Apellis Pharmaceuticals during the first quarter worth approximately $32,329,000. Fiera Capital Corp raised its position in Apellis Pharmaceuticals by 47.7% during the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after purchasing an additional 452,753 shares during the period. AQR Capital Management LLC lifted its stake in shares of Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after purchasing an additional 190,420 shares during the last quarter. Finally, Redmile Group LLC purchased a new position in shares of Apellis Pharmaceuticals in the 1st quarter worth approximately $9,111,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. The trade was a 27.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.80% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Jefferies Financial Group restated a “buy” rating and set a $80.00 price target on shares of Apellis Pharmaceuticals in a report on Wednesday, July 31st. Royal Bank of Canada restated a “sector perform” rating and issued a $25.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, November 4th. UBS Group dropped their price target on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Mizuho reduced their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. Finally, Wells Fargo & Company dropped their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.06.

Apellis Pharmaceuticals Stock Down 0.3 %

NASDAQ:APLS opened at $26.18 on Tuesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $73.80. The company has a 50-day moving average of $29.93 and a 200 day moving average of $36.18. The firm has a market cap of $3.26 billion, a PE ratio of -12.93 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s revenue for the quarter was up 78.3% on a year-over-year basis. During the same period in the previous year, the company posted ($1.17) EPS. As a group, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).